Merck predicts over 80 potential oncology approvals through 2028R&D, TherapeuticsPowered by the company’s blockbuster checkpoint inhibitor Keytruda, Merck is forecasting the potential of more than 80 new regulatory approvals in oncology through 2028. Read more June 7, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2021/10/Merck-Sees-Positive-Signals-for-HIV-Drug-in-Phase-III-BioSpace-10-25-21.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-06-07 10:30:352022-06-07 12:17:31Merck predicts over 80 potential oncology approvals through 2028
